Cardiovascular Systems touts first OUS use of orbital atherectomy system, eyes shift to revascularization

Cardiovascular Systems (NSDQ:CSII) today touted that its peripheral orbital atherectomy system was used in its first procedure outside the US as the company is reportedly looking to grow its business beyond a single product and towards supplying a full revascularization tool kit. The St. Paul, Minn.-based company said that its Stealth 360 peripheral orbital atherectomy system was used to treat a patient in Hong Kong, which marks the first commercial use of the company’s product outside the US. “We are pleased that the first patient treated with OAS in conjunction with our international distribution partner, OrbusNeich, was a success. This positive outcome demonstrates our mutual mission to support physicians in treating patients with peripheral artery disease,” prez & CEO Scott Ward said in a press release. The company is also looking to grow its business from a single-product and a single geographic region into a multi-product multinational that provides “a complete toolkit for revascularization,” according to an analysts letter to investors from Leerink Partner’s Danielle Antalffy. “In its core business, we continue to believe in the company’s significant competitive advantage in both calcified and below-the-knee lesions within peripheral that should drive above market growth, as well as a growing and market-leading position in the highly under-penetrated coronary market. And to us, the long-term guidance is achievable, with...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Vascular Cardiovascular Systems Inc. Source Type: news